ErbB4单克隆抗体(HFR1) | 赛默飞世尔 MA5-13789 产品信息

产品简要

公司名称 :

赛默飞世尔

其他品牌 :

NeoMarkers, Lab Vision, Endogen, Pierce, BioSource International, Zymed Laboratories, Caltag, Molecular Probes, Research Genetics, Life Technologies, Applied Biosystems, GIBCO BRL, ABgene, Dynal, Affinity BioReagents, Nunc, Invitrogen, NatuTec, Oxoid, Richard-Allan Scientific, Arcturus, Perseptive Biosystems, Proxeon, eBioscience

产品类型 :

抗体

产品名称 :

ErbB4单克隆抗体(HFR1)

MA5-13789

规格 :

500微升

价格 :

美国425

克隆性 :

单克隆

宿主 :

小鼠

共轭标签 :

未共轭

克隆名称 :

HFR1

反应物种 :

人类, 小鼠

应用 :

免疫组化

更多信息或购买 :

赛默飞世尔产品网页

文章摘录数: 30

参考文献
Jerjees D, Alabdullah M, Green A, Alshareeda A, Macmillan R, Ellis I, et al. Prognostic and biological significance of proliferation and HER2 expression in the luminal class of breast cancer. Breast Cancer Res Treat. 2014;145:317-30 pubmed 出版商
Thorup M, Munk M, Poulsen S, Gaihede M, Nexo E, Sorensen B, et al. Expression of the epidermal growth factor system in human middle ear cholesteatoma. Acta Otolaryngol. 2014;134:124-34 pubmed 出版商
Paatero I, Lassus H, Junttila T, Kaskinen M, Butzow R, Elenius K. CYT-1 isoform of ErbB4 is an independent prognostic factor in serous ovarian cancer and selectively promotes ovarian cancer cell growth in vitro. Gynecol Oncol. 2013;129:179-87 pubmed 出版商
Ko E, Park S, Cho E, Kim Y, Hwang J, Lee Y, et al. Cystatin M loss is associated with the losses of estrogen receptor, progesterone receptor, and HER4 in invasive breast cancer. Breast Cancer Res. 2010;12:R100 pubmed 出版商
Gulati S, Ytterhus B, Granli U, Gulati M, Lydersen S, Torp S. Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol. 2010;5:18 pubmed 出版商
te Velde E, Franke A, van Hillegersberg R, Elshof S, de Weger R, Borel Rinkes I, et al. HER-family gene amplification and expression in resected pancreatic cancer. Eur J Surg Oncol. 2009;35:1098-104 pubmed 出版商
Altintas S, Lambein K, Huizing M, Braems G, Asjoe F, Hellemans H, et al. Prognostic significance of oncogenic markers in ductal carcinoma in situ of the breast: a clinicopathologic study. Breast J. 2009;15:120-32 pubmed 出版商
Naresh A, Thor A, Edgerton S, Torkko K, Kumar R, Jones F. The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis. Cancer Res. 2008;68:6387-95 pubmed 出版商
Kirkegaard T, Naresh A, Sabine V, Tovey S, Edwards J, Dunne B, et al. Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers. Am J Clin Pathol. 2008;129:735-43 pubmed 出版商
Torp S, Gulati S, Johannessen E, Dalen A. Coexpression of c-erbB 1-4 receptor proteins in human glioblastomas. An immunohistochemical study. J Exp Clin Cancer Res. 2007;26:353-9 pubmed
Sundvall M, Peri L, Määttä J, Tvorogov D, Paatero I, Savisalo M, et al. Differential nuclear localization and kinase activity of alternative ErbB4 intracellular domains. Oncogene. 2007;26:6905-14 pubmed
Giuliani R, Durbecq V, Di Leo A, Paesmans M, Larsimont D, Leroy J, et al. Phosphorylated HER-2 tyrosine kinase and Her-2/neu gene amplification as predictive factors of response to trastuzumab in patients with HER-2 overexpressing metastatic breast cancer (MBC). Eur J Cancer. 2007;43:725-35 pubmed
Ejskjaer K, Sørensen B, Poulsen S, Forman A, Nexø E, Mogensen O. Expression of the epidermal growth factor system in endometrioid endometrial cancer. Gynecol Oncol. 2007;104:158-67 pubmed
Muraoka Cook R, Caskey L, Sandahl M, Hunter D, Husted C, Strunk K, et al. Heregulin-dependent delay in mitotic progression requires HER4 and BRCA1. Mol Cell Biol. 2006;26:6412-24 pubmed
Kountourakis P, Pavlakis K, Psyrri A, Rontogianni D, Xiros N, Patsouris E, et al. Prognostic significance of HER3 and HER4 protein expression in colorectal adenocarcinomas. BMC Cancer. 2006;6:46 pubmed
Rakha E, Putti T, Abd El Rehim D, Paish C, Green A, Powe D, et al. Morphological and immunophenotypic analysis of breast carcinomas with basal and myoepithelial differentiation. J Pathol. 2006;208:495-506 pubmed
Edwards J, Traynor P, Munro A, Pirret C, Dunne B, Bartlett J. The role of HER1-HER4 and EGFRvIII in hormone-refractory prostate cancer. Clin Cancer Res. 2006;12:123-30 pubmed
Leibl S, Bodo K, Gogg Kammerer M, Hrzenjak A, Petru E, Winter R, et al. Ovarian granulosa cell tumors frequently express EGFR (Her-1), Her-3, and Her-4: An immunohistochemical study. Gynecol Oncol. 2006;101:18-23 pubmed
Lee C, Shrieve D, Zempolich K, Lee R, Hammond E, Handrahan D, et al. Correlation between human epidermal growth factor receptor family (EGFR, HER2, HER3, HER4), phosphorylated Akt (P-Akt), and clinical outcomes after radiation therapy in carcinoma of the cervix. Gynecol Oncol. 2005;99:415-21 pubmed
Ejskjaer K, Sørensen B, Poulsen S, Mogensen O, Forman A, Nexø E. Expression of the epidermal growth factor system in human endometrium during the menstrual cycle. Mol Hum Reprod. 2005;11:543-51 pubmed
Prentice L, Shadeo A, Lestou V, Miller M, DeLeeuw R, Makretsov N, et al. NRG1 gene rearrangements in clinical breast cancer: identification of an adjacent novel amplicon associated with poor prognosis. Oncogene. 2005;24:7281-9 pubmed
Hughes D, Thomas D, Giordano T, McDonagh K, Baker L. Essential erbB family phosphorylation in osteosarcoma as a target for CI-1033 inhibition. Pediatr Blood Cancer. 2006;46:614-23 pubmed
Fountzilas G, Pectasides D, Kalogera Fountzila A, Skarlos D, Kalofonos H, Papadimitriou C, et al. Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat. 2005;92:1-9 pubmed
Wiseman S, Makretsov N, Nielsen T, Gilks B, Yorida E, Cheang M, et al. Coexpression of the type 1 growth factor receptor family members HER-1, HER-2, and HER-3 has a synergistic negative prognostic effect on breast carcinoma survival. Cancer. 2005;103:1770-7 pubmed
Caron R, Yacoub A, Zhu X, Mitchell C, Han S, Sasazuki T, et al. H-RAS V12-induced radioresistance in HCT116 colon carcinoma cells is heregulin dependent. Mol Cancer Ther. 2005;4:243-55 pubmed
Abd El Rehim D, Pinder S, Paish C, Bell J, Rampaul R, Blamey R, et al. Expression and co-expression of the members of the epidermal growth factor receptor (EGFR) family in invasive breast carcinoma. Br J Cancer. 2004;91:1532-42 pubmed
Mano M, Awada A, Minisini A, Durbecq V, Di Leo A, Piccart M. Exquisite antitumour response to trastuzumab in a patient with no evidence of Ras-Raf-MAPK and PI3K-Akt pathways activation. Breast. 2004;13:347-9 pubmed
Adélaïde J, Huang H, Murati A, Alsop A, Orsetti B, Mozziconacci M, et al. A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene. Genes Chromosomes Cancer. 2003;37:333-45 pubmed
Yu W, Woessner J, McNeish J, Stamenkovic I. CD44 anchors the assembly of matrilysin/MMP-7 with heparin-binding epidermal growth factor precursor and ErbB4 and regulates female reproductive organ remodeling. Genes Dev. 2002;16:307-23 pubmed
Lammering G, Valerie K, Lin P, Mikkelsen R, Contessa J, Feden J, et al. Radiosensitization of malignant glioma cells through overexpression of dominant-negative epidermal growth factor receptor. Clin Cancer Res. 2001;7:682-90 pubmed

产品信息

产品类型 :

抗体

产品名称 :

ErbB4单克隆抗体(HFR1)

目录# :

MA5-13789

规格 :

500微升

定价 :

美国425

克隆性 :

单克隆

纯度 :

蛋白质A

宿主 :

小鼠

反应物种 :

人类, 小鼠

应用 :

Immunohistochemistry: Assay-dependent

物种 :

人类, 小鼠

克隆 :

HFR1

抗体亚型 :

IgG2b

储存 :

4° C

描述 :

ErbB 4 (Her-4, c-erbB-4, v-erbB-4) is a member of the class I receptor kinase family. With more than 500 gene products, the protein kinase family is one of the largest families of proteins in eukaryotes. The family has been classified in 8 major groups based on sequence comparison of their tyrosine (PTK) or serine/threonine (STK) kinase catalytic domains. ErbB 4 is activated by neuregulins and NTAK (neural and thymus derived activator for ErbB kinases). ErbB 4 is a receptor for heregulin and is capable of mediating HGL-stimulated tyrosine phosphorylation of itself. Like other protein kinases, ErbB 4 mediate most of the signal transduction in eukaryotic cells, regulating cellular metabolism, transcription, cell cycle progression, cytoskeletal rearrangement and cell movement, apoptosis, and differentiation. ErbB 4 is most predominantly expressed in several breast carcinoma cell lines, and in normal skeletal muscle, heart, pituitary, brain, and cerebellum. Breast tumor cell lines T47-D, MDA-MB-453, BT-474 and H3396 are found to have the highest levels of mRNA, and intermediate levels are seen in MCF-7, MDAMB-330 and MDA-MB-361. Expression of ErbB 4 is low or absent in some breast tumor cell lines such as MDA-MB-231, MDA-MB-157, MDA-MB-468, and SKBR-3. ErbB 4 levels have been found to be elevated in certain human tumor cell lines suggesting that it may play a role in some malignancies.

免疫原 :

A synthetic peptide corresponding to aa 1249-1264 (Cys-RSTLQHPDYLQEYST) from the human c-erbB-4/HER-4 oncoprotein

格式 :

液体

应用w/稀释 :

Immunohistochemistry: Assay-dependent

别名 :

4ICD; ALS19; avian erythroblastic leukemia viral (v-erb-b2) oncogene homolog 4; avian erythroblastosis oncogene B 4; c-erbB-4; erb-b2 receptor tyrosine kinase 4; Erbb4; ERBB4 intracellular domain; ERBB4 transcript variant I12DEL; ERBB4 transcript variant I20DEL; Her4; human epidermal growth factor receptor 4; Mer4; OTTHUMP00000209432; p180erbB4; proto-oncogene-like protein c-ErbB-4; receptor tyrosine kinase; receptor tyrosine-protein kinase erbB-4; s80HER4; Tyro-2; Tyrosine kinase-type cell surface receptor HER4; v-erb-a erythroblastic leukemia viral oncogene homolog 4; v-erb-a erythroblastic leukemia viral oncogene homolog 4 (avian); v-erb-b2 avian erythroblastic leukemia viral oncogene 4; v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 4

更多信息或购买 :

赛默飞世尔产品网页

公司信息

赛默飞世尔

上海浦东新金桥路27号7号楼

analyze.cn@thermofisher.com

http://www.thermo.com.cn

1084193588

公司总部: 美国